Refractory extrapulmonary sarcoidosis: infliximab (ES4)Product type:AdviceProgramme:Evidence summaryPublished: 17 January 2017
Pulmonary sarcoidosis: infliximab (ES2)Product type:AdviceProgramme:Evidence summaryPublished: 20 December 2016